Diagnostic Evaluation of Suspected Pheochromocytoma

Initial Biochemical Testing

The American College of Cardiology recommends measurement of plasma free metanephrines or urinary fractionated metanephrines for suspected pheochromocytoma, with plasma free metanephrines being the preferred first-line test due to its superior diagnostic performance (sensitivity 96-100%, specificity 89-98%) 1
Urinary fractionated metanephrines are an acceptable alternative with high sensitivity (86-97%) and specificity (86-95%) 1
Plasma free metanephrines should ideally be collected from an indwelling venous catheter, after the patient has been lying supine for 30 minutes to limit false positive results 1
Plasma methoxytyramine measurement can help assess the likelihood of malignant disease, with a study suggesting its utility in this context 2

Results ≥4 times the upper limit of normal are highly consistent with pheochromocytoma and warrant immediate imaging, according to clinical guidelines 1
Results 2-4 times the upper limit of normal suggest possible pheochromocytoma; repeat testing in 2 months and consider genetic testing, as recommended by clinical guidelines 1
Marginally elevated levels (1-2 times upper limit) may represent false positives; consider repeat testing in 6 months and clonidine suppression test, based on clinical evidence 1

If plasma testing is equivocal (less than fourfold elevation), perform a 24-hour urine collection for catecholamines and metanephrines, as suggested by clinical guidelines 1
Clonidine suppression testing is recommended in cases of equivocal results with strong clinical suspicion (100% specificity, 96% sensitivity), according to clinical evidence 1
Avoid fine needle biopsy of suspected pheochromocytoma as it is contraindicated due to risk of hypertensive crisis, as stated in the Annals of Oncology 2

MRI is preferred for suspected pheochromocytoma due to risk of hypertensive crisis with IV contrast for CT, according to the Annals of Oncology 2
For patients with established pheochromocytoma, FDG-PET appears superior to MIBG for detecting malignant tumors, particularly in patients with SDHB mutation, as reported in the Annals of Oncology 2
If initial imaging is negative but biochemical evidence is positive, extend imaging to include chest and neck, and consider functional imaging, based on clinical guidelines 3

For pediatric patients with suspected hereditary syndromes, begin surveillance with plasma metanephrines at age 6-8 years for hereditary paraganglioma/pheochromocytoma syndromes, or age 2 years for von Hippel-Lindau syndrome, as recommended by clinical guidelines 1
Patients with SDHB mutations require more intensive surveillance due to higher risk of malignancy, according to the Annals of Oncology 2
Plasma free metanephrines can help predict tumor size, location, and presence of metastases, based on clinical evidence 1

Failing to ensure proper patient preparation before testing (medications, posture, fasting status) can lead to false results, as stated in clinical guidelines 1
Relying solely on imaging without biochemical confirmation is not recommended, according to clinical guidelines 3
Not considering extra-adrenal locations when adrenal imaging is negative can lead to missed diagnoses, as reported in clinical guidelines 3
Overlooking the need for specialized imaging protocols optimized for adrenal evaluation can compromise diagnostic accuracy, according to clinical guidelines 3
Performing fine needle biopsy of suspected pheochromocytoma is contraindicated due to risk of hypertensive crisis, as stated in the Annals of Oncology 2